[go: up one dir, main page]

BE2012C005I2 - - Google Patents

Download PDF

Info

Publication number
BE2012C005I2
BE2012C005I2 BE2012C005C BE2012C005C BE2012C005I2 BE 2012C005 I2 BE2012C005 I2 BE 2012C005I2 BE 2012C005 C BE2012C005 C BE 2012C005C BE 2012C005 C BE2012C005 C BE 2012C005C BE 2012C005 I2 BE2012C005 I2 BE 2012C005I2
Authority
BE
Belgium
Prior art keywords
blys
antibodies
present disclosure
related molecules
immunospecifically bind
Prior art date
Application number
BE2012C005C
Other languages
English (en)
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27539647&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2012C005(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of BE2012C005I2 publication Critical patent/BE2012C005I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Analytical Chemistry (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
BE2012C005C 2000-06-16 2012-01-12 BE2012C005I2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US21221000P 2000-06-16 2000-06-16
US24081600P 2000-10-17 2000-10-17
US27624801P 2001-03-16 2001-03-16
US27737901P 2001-03-21 2001-03-21
US29349901P 2001-05-25 2001-05-25
PCT/US2001/019110 WO2002002641A1 (fr) 2000-06-16 2001-06-15 Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b

Publications (1)

Publication Number Publication Date
BE2012C005I2 true BE2012C005I2 (fr) 2020-08-20

Family

ID=27539647

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2012C005C BE2012C005I2 (fr) 2000-06-16 2012-01-12

Country Status (20)

Country Link
US (4) US7138501B2 (fr)
EP (4) EP2281842A1 (fr)
JP (2) JP4902087B2 (fr)
KR (4) KR101287395B1 (fr)
CN (1) CN1279055C (fr)
AT (1) ATE494304T1 (fr)
AU (3) AU6842701A (fr)
BE (1) BE2012C005I2 (fr)
CA (1) CA2407910C (fr)
CY (4) CY1112793T1 (fr)
DE (1) DE60143798D1 (fr)
DK (1) DK1294769T3 (fr)
ES (3) ES2358885T3 (fr)
FR (1) FR12C0001I2 (fr)
HK (1) HK1051697A1 (fr)
LU (1) LU91926I2 (fr)
MX (1) MXPA02012434A (fr)
NZ (1) NZ522700A (fr)
PT (2) PT2275449T (fr)
WO (1) WO2002002641A1 (fr)

Families Citing this family (209)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US7244826B1 (en) * 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
NZ513284A (en) 1999-01-25 2003-10-31 Biogen Inc BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
CA2362204C (fr) 1999-02-17 2011-11-08 John Cooper Cox Complexes immunogenes et methodes y relatives
NZ517782A (en) 1999-08-17 2004-01-30 Biogen Inc A beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
CA2407910C (fr) * 2000-06-16 2013-03-12 Steven M. Ruben Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
US7879328B2 (en) * 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
EP2267016A3 (fr) * 2000-08-18 2011-04-20 Human Genome Sciences, Inc. Polypeptides de liaison pour la protéine stimulatrice des lymphocytes B (BLyS)
WO2002016411A2 (fr) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Polypeptides de fixation et procedes associes
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
WO2002079377A2 (fr) * 2000-11-08 2002-10-10 Human Genome Sciences, Inc. Anticorps a liaison immunospecifique avec les recepteurs 'trail'
US20030119056A1 (en) 2000-12-18 2003-06-26 Ladner Robert Charles Focused libraries of genetic packages
ES2376454T3 (es) * 2000-12-22 2012-03-14 Grad, Carole, Legal Representative Of Howard, Kaplan Librer�?as de expresión en fago de fragmentos vh humanos.
JP2004537290A (ja) * 2001-05-24 2004-12-16 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
MXPA03010747A (es) * 2001-05-25 2004-03-02 Human Genome Sciences Inc Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
JP2004538324A (ja) 2001-08-03 2004-12-24 メディカル リサーチ カウンシル 細胞内抗体
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
US7112410B1 (en) * 2001-08-29 2006-09-26 Human Genome Sciences, Inc. Human tumor necrosis factor TR21 and methods based thereon
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US20030157522A1 (en) * 2001-11-09 2003-08-21 Alain Boudreault Methods and reagents for peptide-BIR interaction screens
WO2003055979A2 (fr) * 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Anticorps se liant à blys selon un mode immunospécifique
AU2002357359B2 (en) * 2001-12-21 2009-01-08 Csl Limited Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
CN1652821A (zh) * 2002-01-28 2005-08-10 米德列斯公司 抗前列腺特异性膜抗原(psma)的人单克隆抗体
CA2481401A1 (fr) * 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Anticorps se liant specifiquement au tl5
WO2003105782A2 (fr) * 2002-06-17 2003-12-24 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Greffage par specificite d'un anticorps murin sur une charpente humaine
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CA2490280A1 (fr) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Anticorps qui se lient specifiquement a reg iv
CA2491669A1 (fr) 2002-07-04 2004-01-15 Oncomab Gmbh Anticorps specifiques de neoplasme et utilisations associees
CA2492457A1 (fr) * 2002-08-02 2004-02-12 Craig A. Rosen Anticorps diriges contre le recepteur c3a
CN1829730A (zh) * 2002-11-12 2006-09-06 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
US7396915B2 (en) 2003-02-28 2008-07-08 Mitsubishi Pharma Corporation Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
JP4914209B2 (ja) 2003-03-14 2012-04-11 ワイス ヒトｉｌ−２１受容体に対する抗体および該抗体の使用
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
US7700317B2 (en) 2003-03-28 2010-04-20 Biogen Idec Ma Inc. Truncated baff receptors
KR100988129B1 (ko) * 2003-04-30 2010-10-18 쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트 인간 항인간 인터루킨-18 항체와 그 단편, 및 이들의이용방법
NZ543712A (en) 2003-06-05 2008-06-30 Genentech Inc Combination therapy for B cell disorders
US7628986B2 (en) 2003-06-27 2009-12-08 Amgen Fremont Inc. Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2005049802A2 (fr) * 2003-11-14 2005-06-02 Massachusetts Institute Of Technology Anticorps anti-hydroxylase et utilisations
EP1531162A1 (fr) 2003-11-14 2005-05-18 Heinz Vollmers Anticorps SAM-6, spécifique d'adénocarcinome, et ses utilisations
DE10353175A1 (de) 2003-11-14 2005-06-16 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper mit fettsenkender Wirkung
WO2005075511A1 (fr) * 2004-01-29 2005-08-18 Genentech, Inc. Variants du domaine extracellulaire de bcma et utilisations de ceux-ci
EP1737487B1 (fr) * 2004-03-30 2016-05-25 Canadian Blood Services Methode servant a traiter des maladies auto-immunes au moyen d'anticorps
CN101921340A (zh) * 2004-03-31 2010-12-22 佳能株式会社 一种蛋白质
JPWO2005105998A1 (ja) * 2004-04-27 2008-07-31 財団法人化学及血清療法研究所 ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
WO2005108986A1 (fr) * 2004-05-10 2005-11-17 Korea Research Institute Of Bioscience And Biotechnology Procede de diagnostic de l'asthme au moyen de baff utilise comme marqueur diagnostique
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
US20080050381A1 (en) * 2004-08-31 2008-02-28 Tsutomu Takeuchi Antihuman Baff Antibody
EP1799260A4 (fr) * 2004-09-29 2011-09-28 Centocor Inc Anticorps anti- amyloide, compositions, techniques et utilisations
NZ560285A (en) * 2005-01-28 2011-04-29 Biogen Idec Inc Use of baff to treat Th2-mediated conditions
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
EP2333066B1 (fr) * 2005-03-25 2015-02-18 National Research Council of Canada Procédé d'isolation de polypeptides solubles
AU2011247831B8 (en) * 2005-03-25 2014-02-20 National Research Council Of Canada Method for isolation of soluble polypeptides
AU2006236588A1 (en) 2005-04-15 2006-10-26 Becton, Dickinson And Company Diagnosis of sepsis
US20060240006A1 (en) * 2005-04-20 2006-10-26 Chishih Chu Novel antibody structures derived from human germline sequences
NZ597082A (en) * 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
JP4736037B2 (ja) * 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
AU2006318539B2 (en) * 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
AU2007209201A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
JP2007306828A (ja) * 2006-05-17 2007-11-29 Tokai Univ 非還元マンノース残基を認識するファージ提示型単鎖抗体
US7981417B2 (en) * 2006-06-07 2011-07-19 Wisconsin Alumni Research Foundation Blood-brain barrier targeting anti-bodies
CA2653444A1 (fr) * 2006-06-07 2007-12-13 Wisconsin Alumni Research Foundation Anticorps ciblant la barriere hemato-encephalique
EP2078732B1 (fr) * 2006-07-10 2015-09-16 Fujita Health University Procédé pour l'identification des anticorps diagnostic ou thérapeutiques par cytométrie en flux
CA2665644A1 (fr) * 2006-10-12 2008-05-29 Genentech, Inc. Anticorps de la lymphotoxine-alpha
WO2008140483A2 (fr) * 2006-11-09 2008-11-20 Human Genome Sciences, Inc. Procédés et anticorps pour détecter un antigène protecteur
PL2104682T3 (pl) 2007-01-11 2017-03-31 Michael Bacher Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
WO2009029132A2 (fr) * 2007-05-31 2009-03-05 Merck & Co., Inc. PROTÉINES DE LIAISON À L'ANTIGÈNE CIBLANT L'ORF0657n DE S. AUREUS
CL2008002153A1 (es) 2007-07-24 2009-06-05 Amgen Inc Anticuerpo aislado o fragmanto de unión de antigeno del mismo que se une al receptor de il-18 (il-18r); molecula de ácido nucleico codificante; celula huesped que la comprende; composición farmaceutica; uso médico para tratar o prevenir una condición asociada con il-18r; método in vitro para inhibir la unión de il-18 al il-18r.
CA2695237A1 (fr) * 2007-08-02 2009-04-30 Novimmune S.A. Anticorps anti-rantes et leurs procedes d'utilisation
KR20100040951A (ko) 2007-08-09 2010-04-21 신토닉스 파마수티칼스, 인코포레이티드 면역조절성 펩티드
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
PL2233149T3 (pl) 2007-10-16 2016-08-31 Zymogenetics Inc Kombinacja przezbłonowego aktywatora i ligandu cyklofiliny (taci) oraz przeciwciała anty-cd20 do leczenia chorób autoimmunologicznych
UY31466A1 (es) * 2007-11-13 2009-07-17 Anticuerpos monoclonales que se unen al hgm-csf y las composiciones médicas que los comprenden
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
BRPI0911431B8 (pt) * 2008-04-11 2021-05-25 Chugai Pharmaceutical Co Ltd composição farmacêutica compreendendo um antígeno e método para aumentar o número de antígenos que podem ser ligados por um anticorpo
CA2721202A1 (fr) * 2008-04-17 2009-10-22 Hilde Adi Pierrette Revets Peptides capables de se lier a des proteines seriques et composes, constructions et polypeptides les comprenant
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
US8003335B2 (en) 2008-04-30 2011-08-23 Universite Paris-SUD11 Levels of APRIL in serum and use in diagnostic methods
PL2291657T3 (pl) 2008-05-01 2016-09-30 Stężenie heterotrimerów blys/april w surowicy oraz zastosowanie w sposobach diagnostycznych
US20100322936A1 (en) * 2008-06-16 2010-12-23 Patrys Limited Lm-1 antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
UA112050C2 (uk) * 2008-08-04 2016-07-25 БАЄР ХЕЛСКЕР ЛЛСі Терапевтична композиція, що містить моноклональне антитіло проти інгібітора шляху тканинного фактора (tfpi)
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
EP2344541A2 (fr) * 2008-09-19 2011-07-20 MedImmune, LLC Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2376120A2 (fr) 2008-11-25 2011-10-19 Biogen Idec MA Inc. Utilisation d'antagonistes dr6 et p75 pour favoriser la survie de cellules du systeme nerveux
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
WO2010093993A2 (fr) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Utilisation d'antagonistes de la protéine stimulant les lymphocytes b afin de favoriser la tolérance aux greffes
RU2595379C2 (ru) * 2009-04-16 2016-08-27 АббВай Биотерапеутикс Инк. АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ
WO2010141249A2 (fr) * 2009-06-02 2010-12-09 Merck Sharp & Dohme Corp. Génération, caractérisation et utilisations d'anticorps anti-notch3
RU2539112C2 (ru) 2009-09-03 2015-01-10 Дженентек, Инк. Способы лечения, диагностики и мониторинга ревматоидного артрита
PT2542257T (pt) 2010-03-01 2017-10-09 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
WO2011109280A1 (fr) 2010-03-05 2011-09-09 Lerner Research Institute Procédés et compositions permettant de traiter les troubles d'origines immunes
WO2011139375A1 (fr) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Anticorps dirigés contre l'anhydrase carbonique ix et méthodes et utilisations associées
WO2011160086A2 (fr) * 2010-06-18 2011-12-22 Human Genome Sciences, Inc. Utilisation d'antagonistes d'une protéine stimulant les lymphocytes b en vue du traitement de l'asthme et d'autres affections allergiques et inflammatoires du système respiratoire
CA2806076A1 (fr) 2010-07-22 2012-01-26 The Regents Of The University Of California Anticorps-antigenes antitumoraux et methodes d'utilisation correspondantes
AP3584A (en) 2010-09-22 2016-02-09 Alios Biopharma Inc Substituted nucleotide analogs
WO2012047583A2 (fr) * 2010-09-27 2012-04-12 Janssen Biotech, Inc. Anticorps se liant au collagène humain de type ii
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
JP6030452B2 (ja) 2010-11-30 2016-11-24 中外製薬株式会社 複数分子の抗原に繰り返し結合する抗原結合分子
WO2012099973A2 (fr) * 2011-01-18 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions et procédés de traitement du cancer
KR20230005405A (ko) 2011-02-25 2023-01-09 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ 항체
EP2680884B1 (fr) 2011-02-28 2018-01-17 F. Hoffmann-La Roche AG Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b
DE102011006809A1 (de) 2011-04-05 2012-10-11 Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten
ES3005912T3 (en) 2011-07-22 2025-03-17 Csl Behring Gmbh Inhibitory anti-factor xii/xiia monoclonal antibodies and their uses
JP6277126B2 (ja) * 2011-08-09 2018-02-07 アセラ・バイオテクノロジーズ・アーベー ホスホリルコリン（ｐｃ）および／またはｐｃコンジュゲートに結合する抗体
WO2013047748A1 (fr) 2011-09-30 2013-04-04 中外製薬株式会社 Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CA2860234A1 (fr) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Analogues de nucleotide phosphorothioate substitue
US9175072B2 (en) * 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US10745468B2 (en) * 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
WO2013106572A1 (fr) 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Fragments d'anticorps bispécifiques pour protéines associées à une maladie neurologique, et procédés d'utilisation
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (fr) 2012-03-22 2015-10-28 Alios Biopharma Inc Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
US9107904B2 (en) * 2012-04-05 2015-08-18 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
CN103421113B (zh) * 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
US10174107B2 (en) 2012-05-31 2019-01-08 Sorrento Therapeutics, Inc. Antigen binding proteins that bind delta-like 4 (DLL-4)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CA2881966C (fr) 2012-08-24 2020-10-06 The Regents Of The University Of California Anticorps et vaccins utilisables en vue du traitement de cancers ror1 et de l'inhibition de la metastase
EA201590459A1 (ru) * 2012-09-12 2015-11-30 Нейриммьюн Холдинг Аг Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
US9458246B2 (en) * 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) * 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
BR112015021399A2 (pt) 2013-03-14 2017-07-18 Bayer Healthcare Llc anticórpos monoclonais contra antitrombina beta complexada com heparina
PT3508502T (pt) 2013-09-20 2023-06-22 Bristol Myers Squibb Co Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112016014072B1 (pt) 2013-12-17 2023-12-26 Kling Biotherapeutics B.V. Anticorpo isolado, sintético ou recombinante humano, ou uma parte funciona do mesmo, molécula de ácido nucleico isolado, vetor, composição, uso de um anticorpo ou parte funcional, ou uma molécula de ácido nucleico ou um vetor e, métodos para produzir um anticorpo ou parte funcional, e para determinar se céuluas aml ou células de linfoma ou células de mieloma múltiplo ou células b de linfoma não hodgkin estão presentes em uma amostra
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
CN104804091B (zh) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体及用途
CN104804090B (zh) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体和用途
CN104804092B (zh) * 2014-01-29 2018-03-27 天津胜发生物技术有限公司 一种抗b细胞生长刺激因子的纳米抗体及其用途
JP6511459B2 (ja) 2014-01-31 2019-05-15 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規な抗ｂａｆｆ抗体
SI3116909T1 (sl) 2014-03-14 2020-03-31 Novartis Ag Molekule protiteles na LAG-3 in njih uporaba
US10758526B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
US11034757B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US10434174B2 (en) 2014-06-09 2019-10-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
WO2015191590A2 (fr) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Polythérapies ciblant des stromas associés à une tumeur ou des cellules tumorales et des microtubules
US10758614B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2015191615A2 (fr) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Polythérapies utilisant des agents qui ciblent un stroma associé à une tumeur ou des cellules tumorales et des agents alkylants
WO2015191602A2 (fr) * 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Polythérapies ciblant un stroma associé à une tumeur ou des cellules tumorales
US10758613B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Intstitutes Of Health Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
US9683017B2 (en) 2014-07-17 2017-06-20 University Tennessee Research Foundation Inhibitory peptides of viral infection
WO2016032949A1 (fr) 2014-08-26 2016-03-03 University Of Tennessee Research Foundation Immunothérapie de ciblage de l'amyloïdose
EP3215175A4 (fr) * 2014-11-06 2018-06-27 Scholar Rock, Inc. Anticorps anti-pro-myostatine/myostatine latente et leurs utilisations
HRP20211978T1 (hr) 2014-12-05 2022-04-01 Memorial Sloan-Kettering Cancer Center Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe
MX2017007246A (es) * 2014-12-05 2018-01-25 Memorial Sloan Kettering Cancer Center Anticuerpos orientados al antigeno de maduracion de celula b y metodos de uso.
MX2017007249A (es) 2014-12-05 2018-01-25 Memorial Sloan Kettering Cancer Center Receptores de antigeno quimerico dirigidos al receptor fc 5 similar y sus usos.
IL295298A (en) 2014-12-05 2022-10-01 Memorial Sloan Kettering Cancer Center All B-cell maturation antigen-directed chimeric antigen receptors and their uses
CA2967554A1 (fr) 2014-12-19 2016-06-23 Yoshinao Ruike Anticorps anti-c5 et leurs procedes d'utilisation
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
JP6865688B2 (ja) 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
TW202248212A (zh) 2015-02-05 2022-12-16 日商中外製藥股份有限公司 包含離子濃度依賴之抗原結合域的抗體、Fc區變體、IL-8結合抗體與其用途
CN108271359B (zh) * 2015-02-13 2021-11-09 索伦托药业有限公司 结合ctla4的抗体治疗剂
RU2730590C2 (ru) 2015-02-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Композиция для лечения заболеваний, связанных с ил-6
AR104368A1 (es) 2015-04-03 2017-07-19 Lilly Co Eli Anticuerpos biespecíficos anti-cd20- / anti-baff
WO2016164530A1 (fr) * 2015-04-07 2016-10-13 University Of Maryland, College Park Compositions et procédés pour le séquençage de protéines à haut débit
CN113527495A (zh) 2015-04-08 2021-10-22 索伦托药业有限公司 与cd38结合的抗体治疗剂
US10618976B2 (en) 2015-06-16 2020-04-14 The Board Of Trustees Of The Leland Stanford Junior University SIRP-α agonist antibody
SG10201912593VA (en) 2015-07-23 2020-02-27 Boehringer Ingelheim Int Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
MA48579A (fr) 2015-09-01 2020-03-18 Agenus Inc Anticorps anti-pd1 et méthodes d'utilisation de ceux-ci
CN113896790A (zh) 2015-09-15 2022-01-07 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其用途
SG11201804656PA (en) 2015-12-04 2018-06-28 Memorial Sloan Kettering Cancer Center Antibodies targeting fc receptor-like 5 and methods of use
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
MX2018009011A (es) 2016-02-02 2018-11-19 Hutchinson Fred Cancer Res Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
EP3416687A4 (fr) 2016-02-17 2019-10-23 Seattle Genetics, Inc. Anticorps bcma et leur utilisation pour traiter le cancer et les troubles immunologiques
WO2017184973A1 (fr) * 2016-04-22 2017-10-26 University Of Tennessee Research Foundation Identification des protéines amyloïdogènes et du risque amyloïdogène
EP3785728A3 (fr) 2016-06-13 2021-04-28 Scholar Rock, Inc. Utilisation d'inhibiteurs de la myostatine et thérapies combinées
CN109996544A (zh) 2016-06-27 2019-07-09 加利福尼亚大学董事会 癌症治疗组合
IL264161B1 (en) * 2016-07-14 2025-02-01 Scholar Rock Inc TGFB Antibodies, Methods and Uses
US10300145B2 (en) 2016-07-15 2019-05-28 Massachusetts Institute Of Technology Synthetic nanoparticles for delivery of immunomodulatory compounds
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018039107A1 (fr) * 2016-08-22 2018-03-01 Medimmune, Llc Molécules de liaison spécifiques pour notch4 et leurs utilisations
WO2018035710A1 (fr) * 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anticorps anti-ctla4
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
RS64159B1 (sr) 2017-01-06 2023-05-31 Scholar Rock Inc Tretiranje metaboličkih bolesti inhibiranjem aktivacije miostatina
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
BR112019017120A8 (pt) 2017-02-17 2023-05-02 Hutchinson Fred Cancer Res Terapias de combinação para tratamento de cânceres e distúrbios autoimunes relacionados a bcma
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
DK3631454T3 (da) 2017-05-30 2023-12-04 Bristol Myers Squibb Co Behandling af lag-3 positive tumorer
WO2018222722A2 (fr) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Compositions comprenant un anticorps anti-lag-3 ou un anticorps anti-lag-3 et un anticorps anti-pd-1 ou anti-pd-l1
WO2019079249A1 (fr) 2017-10-16 2019-04-25 Lentigen Technology, Inc. Compositions et méthodes pour le traitement du cancer avec une immunothérapie anti-cd22
MX2020004243A (es) 2017-11-01 2020-09-25 Juno Therapeutics Inc Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
CN111902159A (zh) 2017-11-01 2020-11-06 朱诺治疗学股份有限公司 对b细胞成熟抗原（bcma）具有特异性的嵌合抗原受体
BR112020008812A2 (pt) 2017-11-06 2020-10-27 Juno Therapeutics Inc combinação de terapia celular e um inibidor de gama secretase
KR20200140265A (ko) 2018-03-02 2020-12-15 엘리시오 테라퓨틱스, 인크. Cpg 양친매성 물질 및 이의 용도
MA53381A (fr) * 2018-07-24 2021-06-02 Amgen Inc Association d'inhibiteurs de la voie lilrb1/2 et d'inhibiteurs de la voie pd-1
MX2021005808A (es) 2018-11-20 2021-07-02 Univ Cornell Complejos macrociclicos de radionucleidos alfa-emisores y su uso en radioterapia focalizada de cancer.
KR20220002891A (ko) 2019-03-15 2022-01-07 모르포시스 아게 자가항체-매개 자가면역 질병의 치료를 위한 항-cd38 항체 및 이의 약제학적 조성물
AU2021253821A1 (en) * 2020-04-08 2022-11-24 Aliada Therapeutics, Inc. Anti-CD98 antibodies and uses thereof
US20230212266A1 (en) * 2020-04-27 2023-07-06 Fred Hutchinson Cancer Center Neutralizing monoclonal antibodies against covid19
IL297981A (en) 2020-05-08 2023-01-01 Alpine Immune Sciences Inc Immunomodulatory proteins that inhibit april and baff together with and without a t-cell suppressor protein and methods of using them
WO2022132887A1 (fr) * 2020-12-15 2022-06-23 Board Of Regents, The University Of Texas System Anticorps monoclonaux humains ciblant la protéine de spicule du sars-cov-2
BR112023022133A2 (pt) 2021-05-07 2023-12-26 Viela Bio Inc Uso de um anticorpo anti-cd19 para tratar miastenia gravis
KR20240038773A (ko) 2021-07-27 2024-03-25 아스트라제네카 아베 루푸스의 치료
CN117003872A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
TW202404639A (zh) * 2022-07-19 2024-02-01 瑞士商諾華公司 Aiha之治療

Family Cites Families (244)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5576195A (en) * 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
EP0247091B1 (fr) 1985-11-01 1993-09-29 Xoma Corporation Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
EP0428534B1 (fr) 1988-06-14 1995-03-29 Cetus Oncology Corporation Agents de couplage et conjugues lies a des disulfures a empechement sterique prepares a partir de tels agents
NZ229700A (en) 1988-06-24 1993-01-27 Dow Chemical Co Tetraazacyclododecane derivatives containing a linker/spacer moiety capable of forming antibody conjugates; complexes with radionuclides and conjugates of such compounds and complexes with antibodies or antibody fragments
CN1033030C (zh) 1988-06-24 1996-10-16 唐化学原料公司 大环双官能螯合剂及其配合物和抗体共轭物的制备方法
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (fr) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Polypeptides chimériques de CD4-immunoglobuline
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
CA2062795A1 (fr) 1989-06-29 1990-12-30 Michael W. Fanger Reactifs bispecifiques pour le traitement du sida
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
GB8923843D0 (en) * 1989-10-23 1989-12-13 Salutar Inc Compounds
WO1991006570A1 (fr) 1989-10-25 1991-05-16 The University Of Melbourne MOLECULES RECEPTRICES Fc HYBRIDES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
WO1991010741A1 (fr) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation d'anticorps xenogeniques
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
WO1991014438A1 (fr) 1990-03-20 1991-10-03 The Trustees Of Columbia University In The City Of New York Anticorps chimeriques utilisant des ligands de liaison de recepteurs a la place de leur region constante
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5635384A (en) * 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0814159B1 (fr) 1990-08-29 2005-07-27 GenPharm International, Inc. Souris transgéniques capables de produire des anticorps hétérologues
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
JP3583420B2 (ja) 1990-10-05 2004-11-04 メダレツクス・インコーポレーテツド 二特異的試薬を用いた標的免疫化
EP0557300B1 (fr) 1990-10-29 1997-11-19 Chiron Corporation Anticorps bispecifiques, methodes de production et utilisation desdits anticorps
EP0574395B1 (fr) 1990-11-09 2002-06-12 GILLIES, Stephen D. Immunoconjugues de cytokine
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK0517895T3 (da) 1990-12-14 1997-04-07 Univ California Kimæriske kæder til receptorforbundne signaltransduktionsveje
DK0577752T4 (da) 1991-03-29 2007-10-22 Genentech Inc Human PF4A receptorer og deres anvendelse
DE69233367T2 (de) 1991-04-10 2005-05-25 The Scripps Research Institute, La Jolla Bibliotheken heterodimerer rezeptoren mittels phagemiden
JP3431140B2 (ja) 1991-04-26 2003-07-28 サーフィス・アクティブ・リミテッド 抗体およびその使用方法
DK0584279T3 (da) 1991-05-14 2001-06-11 Immune Response Corp Inc Målrettet aflevering af gener, som koder for immunogene proteiner
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
ATE195656T1 (de) 1991-06-05 2000-09-15 Univ Connecticut Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
EP0590067A1 (fr) 1991-06-14 1994-04-06 Xoma Corporation Fragments d'anticorps produits par des microbes et leurs conjugues
IL99120A0 (en) 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5376546A (en) 1991-11-04 1994-12-27 Xoma Corporation Analogs of ribosome-inactivating proteins
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE239506T1 (de) 1992-03-05 2003-05-15 Univ Texas Verwendung von immunokonjugate zur diagnose und/oder therapie der vaskularisierten tumoren
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
WO1993020221A1 (fr) 1992-04-03 1993-10-14 Young Alexander T Therapie genique utilisant des vecteurs viraux cibles
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
DE69325777T2 (de) 1992-06-09 2000-03-09 Hoppe Ag Riegel und türschloss
US5962301A (en) 1992-06-12 1999-10-05 Massachusetts Institute Of Technology Relatedness of human interleukin-1β convertase gene to a C. elegans cell death gene, inhibitory portions of these genes and uses therefor
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
EP0749475A4 (fr) 1992-08-26 1997-05-07 Harvard College Utilisation de la cytokine ip-10 comme agent antitumeur
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5605671A (en) * 1992-10-05 1997-02-25 The Regents Of The University Of Michigan Radiolabeled neutrophil activating peptides for imaging
AU689758B2 (en) 1992-10-09 1998-04-09 Advanced Tissue Sciences, Inc. Liver reserve cells
US5869331A (en) 1992-11-20 1999-02-09 University Of Medicine & Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5589499A (en) 1992-11-25 1996-12-31 Weth; Gosbert Dopaminergic agents for the treatment of cerebral and peripheral blood flow disorders
EP0905253A3 (fr) 1992-12-03 2000-11-02 Genzyme Corporation Vecteur adenovira délété de tous les ORF de E4 excepté ORF6
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
EP0652231A1 (fr) 1993-03-02 1995-05-10 Universidad De Valladolid PROTEINES INACTIVATRICES DE RIBOSOMES (RIPs) A DEUX CHAINES NON TOXIQUES, PROCEDE POUR LEUR PREPARATION ET APPLICATIONS
DE69415026D1 (de) 1993-09-06 1999-01-14 Menarini Richerche Sud S P A Ribosom-inaktievirende proteine, die aus saponaria ocymoides und vaccaria pyramidata samen extrahiert sind sowie deren herstellung und immunotoxine, die sie enthalten
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU696293B2 (en) 1993-12-08 1998-09-03 Genzyme Corporation Process for generating specific antibodies
US5597709A (en) 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) * 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5817485A (en) 1994-03-08 1998-10-06 Human Genome Sciences, Inc. Nucleic acids and cells for recombinant production of fibroblast growth factor-10
US5633147A (en) 1994-03-08 1997-05-27 Human Genome Sciences, Inc. Transforming growth factor αH1
AU7394294A (en) 1994-05-16 1995-12-05 Human Genome Sciences, Inc. Macrophage migration inhibitory factor-3
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
BR9508469A (pt) 1994-07-29 1997-09-16 Smithkline Beecham Plc Proteína solúvel tendo antagonista il4 e/ou il13 ou atividade antagonista parcial composto processo para a preparação do mesmo polímero de DNA vetor de exemplo replicável célula hospedeira composição farmacêutica processo para tratar condições e uso do composto
EP0792278B1 (fr) 1994-11-07 2007-06-13 Human Genome Sciences, Inc. Polypeptide gamma appartenant a la famille des facteurs de necrose tumorale (fnt)
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
WO1996022024A1 (fr) 1995-01-17 1996-07-25 Brigham And Women's Hospital, Inc. Transport transepithelial specifique de recepteurs d'immunogenes
AU2363695A (en) 1995-04-27 1996-11-18 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
CA2761116A1 (fr) 1995-04-27 1996-10-31 Amgen Fremont Inc. Anticorps humains derives d'une xenosouris immunisee
CA2219486A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6635492B2 (en) 1996-01-25 2003-10-21 Bjs Company Ltd. Heating specimen carriers
WO1997033904A1 (fr) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Recepteurs contenant un domaine de mort cellulaire
WO1997033899A1 (fr) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Molecule i induisant l'apoptose
ATE254135T1 (de) 1996-03-14 2003-11-15 Human Genome Sciences Inc Humaner tumornekrosefaktor delta und epsilon
US6541224B2 (en) * 1996-03-14 2003-04-01 Human Genome Sciences, Inc. Tumor necrosis factor delta polypeptides
KR20030096450A (ko) 1996-03-22 2003-12-31 휴먼 게놈 사이언시즈, 인코포레이티드 고사 유도 분자 ⅱ
US5792850A (en) 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
US6300065B1 (en) * 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
AU734638B2 (en) 1996-06-06 2001-06-21 Lajolla Pharmaceutical Company aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
IT1286663B1 (it) 1996-06-27 1998-07-15 Ministero Uni Ricerca Scient E Proteina capace di inibire l'attivita' ribosomiale,sua preparazione ed uso come immunoconiugato chimico o ricombinante e sequenza di cdna
CA2263129C (fr) 1996-08-16 2007-01-09 Schering Corporation Antigenes de surface de cellules mammaliennes et reactifs qui y sont lies
NZ334035A (en) 1996-08-16 2000-09-29 Human Genome Sciences Inc Use of endokine alpha antagonists to diagnose and treat TNF-related disorders
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020115112A1 (en) * 1999-02-23 2002-08-22 Human Genome Sciences, Inc. Neutrokine-alpha and Neutrokine-alpha splice variant
WO1998018921A1 (fr) 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
US6689579B1 (en) * 1996-10-25 2004-02-10 Human Genome Sciences, Inc. Polynucleotides encoding neutrokine-α
US20030175208A1 (en) * 1996-10-25 2003-09-18 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) * 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
WO1999035170A2 (fr) 1998-01-05 1999-07-15 Genentech, Inc. Compositions et methodes pour le traitement des tumeurs
EP2305027B1 (fr) 1996-12-03 2014-07-02 Amgen Fremont Inc. Mammifères trangèniques obtenus par génie génétique contenant des loci des immunoglobulines humaines qui comprennent plusieurs régions de VH et de Vkappa, et anticorps aussi obtenus.
AU5705898A (en) 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
AU6238698A (en) 1997-01-14 1998-08-03 Human Genome Sciences, Inc. Tumor necrosis factor receptor 5
ES2286843T3 (es) 1997-01-14 2007-12-01 Human Genome Sciences, Inc. Receptores 6 alfa y 6 beta del factor de necrosis tumoral.
DK1012274T4 (da) 1997-01-28 2011-07-25 Human Genome Sciences Inc Dødsdomæneholdig receptor-4 (DR4: dødsreceptor 4), medlem af TNF-receptorsuperfamilien og som binder til TRAIL (Apo-2L)
US5969102A (en) 1997-03-03 1999-10-19 St. Jude Children's Research Hospital Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
NZ337795A (en) 1997-03-17 2001-06-29 Human Genome Sciences Inc Death domain containing receptor 5 and it's use in the treatment of DR5 related disease
CA2232743A1 (fr) 1997-04-02 1998-10-02 Smithkline Beecham Corporation Tl5, homologue tnf
TR199902553T2 (xx) 1997-04-14 2000-03-21 Micromet Gesellschaft F�R Biomedizinische Forschung Mbh �nsan v�cuduna kar�� antijen resept�rlerinin �retimi i�in yeni metod ve kullan�mlar�.
JP2002514079A (ja) 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
DK1798288T3 (da) 1997-05-07 2010-01-04 Schering Corp Humane Toll-lignende receptorproteiner, relaterede reagenser og fremgangsmåder
WO1998054202A1 (fr) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Recepteur tr10 du facteur de necrose tumorale humain
JP2002504818A (ja) 1997-06-06 2002-02-12 リジェネロン ファーマシューティカルズ，インコーポレイテッド リガンドファミリーのｎｔｎ−２メンバー
AU7608898A (en) 1997-06-06 1998-12-21 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
EP0975762B1 (fr) 1997-06-06 2011-10-05 PanGenetics B.V. Proteine de type 1 inactivant un ribosome
WO1998056892A1 (fr) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Recepteur humain tr9 du facteur de necrose tumorale
US5948619A (en) 1997-07-31 1999-09-07 Incyte Pharmaceuticals, Inc. Human zygin-1
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999011791A2 (fr) 1997-09-05 1999-03-11 University Of Washington Recepteurs et ligands de la famille du facteur de necrose tumorale, acides nucleiques codants et agents de liaison associes
TR200000654T2 (tr) 1997-09-12 2000-07-21 Apotech R & D Sa KAY-Yeni bir bağışıklık sistemi proteini.
US5795724A (en) * 1997-09-12 1998-08-18 Incyte Pharmaceuticals, Inc. Human N-acetyl transferase
MXPA00004256A (es) 1997-11-03 2005-07-01 Human Genome Sciences Inc Inhibidor de las celulas endoteliales vasculares, un inhibidor de la angiogenesis y crecimiento del tumor.
US20020055624A1 (en) * 1997-11-17 2002-05-09 Steven R. Wiley Tnf-delta ligand and uses thereof
US20010010925A1 (en) * 1997-11-17 2001-08-02 Steven R. Wiley Methods of detecting target nucleic acids of tnf-delta
JP2002503444A (ja) 1997-11-26 2002-02-05 イーライ・リリー・アンド・カンパニー リガンドファミリー遺伝子
WO1999033980A2 (fr) 1997-12-30 1999-07-08 Chiron Corporation Membres de familles de tnf et de tnfr
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
WO1999046295A1 (fr) 1998-03-12 1999-09-16 Shanghai Second Medical University Gene homologue au gene b(2)gene de drosophile et proteine ypr015c de levure putative 26,5kd
WO1999047538A1 (fr) 1998-03-19 1999-09-23 Human Genome Sciences, Inc. Analogue de chaine gamma commune de recepteur de cytokine
CA2294364A1 (fr) 1998-04-20 1999-10-28 Lss Life Support Systems Ag Tenue vestimentaire de protection contre les effets de l'acceleration
EP1076703B2 (fr) 1998-05-15 2010-12-15 Genentech, Inc. Utilisations therapeutiques de polypeptides homologues de il-17
WO2000026244A2 (fr) 1998-11-04 2000-05-11 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nouveau membre de la famille des facteurs de necrose des tumeurs, ligand du recepteur de la mort cellulaire (drl) et compositions et procedes correspondants
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US6297637B1 (en) * 1998-12-29 2001-10-02 Siemens Aktiengesellschaft High-frequency receiver, particularly for a nuclear magnetic resonance apparatus
DE60043626D1 (de) 1999-01-07 2010-02-11 Zymogenetics Inc Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
NZ513284A (en) * 1999-01-25 2003-10-31 Biogen Inc BAFF blocking agents and their use in the stimulation and inhibition of B-cells and immunoglobulins in immune responses
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US20050100548A1 (en) 2001-07-24 2005-05-12 Biogen Idec Ma Inc. BAFF, inhibitors thereof and their use in the modulation of B-cell response
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
AU2880400A (en) 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
NZ513290A (en) 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
WO2000058362A1 (fr) 1999-03-26 2000-10-05 Human Genome Sciences, Inc. Nouvelles proteines capables de liaison avec la neutrokine alpha et procedes bases sur lesdites proteines
US20030022233A1 (en) * 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AU4986700A (en) * 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
AU5308200A (en) 1999-06-11 2001-01-02 Human Genome Sciences, Inc. 48 human secreted proteins
NZ517782A (en) 1999-08-17 2004-01-30 Biogen Inc A beta-cell activating factor receptor belonging to the TNF family is used as a pharmaceutical agent and in the treatment of disease
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
EP1669371A3 (fr) 1999-12-01 2006-06-21 Genentech, Inc. Composition et procédés de diagnostic de tumeurs
AU2001234953B2 (en) * 2000-02-11 2006-03-16 Biogen Ma Inc. Heterologous polypeptide of the tnf family
IL150755A0 (en) 2000-02-16 2003-02-12 Genentech Inc Uses of agonists and antagonists to modulate activity of tnf-related molecules
ES2271004T3 (es) 2000-04-27 2007-04-16 Biogen Idec Ma Inc. Uso de taci como agente antitumoral.
ES2287130T3 (es) * 2000-05-12 2007-12-16 Amgen Inc. Polipeptidos para inhibir la proliferacion de celulas b y t inducida por april.
CA2413160A1 (fr) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Facteur de necrose tumorale humain delta et epsilon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
CA2407910C (fr) * 2000-06-16 2013-03-12 Steven M. Ruben Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte b
JP2004512262A (ja) * 2000-06-20 2004-04-22 アイデック　ファーマスーティカルズ　コーポレイション 非放射性抗ｃｄ２０抗体／放射標識抗ｃｄ２２抗体の組合せ
EP1309718A4 (fr) 2000-08-15 2004-08-25 Human Genome Sciences Inc Neutrokine-alpha et variant d'epissage de neutrokine-alpha
WO2002016411A2 (fr) 2000-08-18 2002-02-28 Human Genome Sciences, Inc. Polypeptides de fixation et procedes associes
EP2267016A3 (fr) * 2000-08-18 2011-04-20 Human Genome Sciences, Inc. Polypeptides de liaison pour la protéine stimulatrice des lymphocytes B (BLyS)
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US20030092164A1 (en) 2000-11-07 2003-05-15 Gross Jane A. Human tumor necrosis factor receptor
EP1362061A2 (fr) 2001-02-20 2003-11-19 ZymoGenetics, Inc. Anticorps liant a la fois bcma et taci
DK1385882T3 (da) * 2001-05-11 2008-02-11 Amgen Inc Peptider og relaterede molekyler, der binder til TALL-1
CN1612750B (zh) 2001-05-24 2012-10-31 津莫吉尼蒂克斯公司 Taci-免疫球蛋白融合蛋白质
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
JP4002082B2 (ja) 2001-09-14 2007-10-31 古河電気工業株式会社 光ファイバ母材およびその製造方法
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
WO2003033658A2 (fr) 2001-10-17 2003-04-24 Human Genome Sciences, Inc. Neutrokine-alpha et variant d'epissage de neutrokine-alpha
US20050054567A1 (en) 2001-11-06 2005-03-10 Rowlinson Scott William Use of il-19,il-22 and il-24 to treat hematopoietic disorders
WO2003055979A2 (fr) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. Anticorps se liant à blys selon un mode immunospécifique
US20020150579A1 (en) * 2002-01-10 2002-10-17 Kimberly Robert P. B lymphocyte stimulator (BLyS) as a marker in management of systemic lupus erythematosus
WO2003072713A2 (fr) 2002-02-21 2003-09-04 Biogen Idec Ma Inc. Utilisation de bcma comme agent immunoregulateur
AU2003299819A1 (en) 2002-12-23 2004-07-22 Human Genome Sciences, Inc. Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
WO2004074511A1 (fr) 2003-02-21 2004-09-02 Garvan Institute Of Medical Research Diagnostic et traitement des maladies auto-immunes mediees par baff et du cancer
US20050163775A1 (en) 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
NZ543712A (en) 2003-06-05 2008-06-30 Genentech Inc Combination therapy for B cell disorders
RU2006117324A (ru) 2003-10-20 2007-12-10 Байоджен Айдек Ма Инк. (Us) Терапевтические режимы для антагонистов baff
DE10355251A1 (de) 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
NZ560285A (en) 2005-01-28 2011-04-29 Biogen Idec Inc Use of baff to treat Th2-mediated conditions
US20060171919A1 (en) * 2005-02-01 2006-08-03 Research Development Foundation Targeted polypeptides
US20090215071A1 (en) 2005-07-28 2009-08-27 Teresa Cachero Methods of targeting baff
NZ597082A (en) 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
RS52888B (en) 2007-03-27 2014-02-28 Zymogenetics Inc. COMBINATION OF BLYS INHIBITION AND MYPHOPHENOLATE MOFETILE FOR THE TREATMENT OF AUTOMMUNE DISEASE
AU2009239437B2 (en) 2008-04-25 2014-11-13 University Of Washington Levels of BCMA protein expression on B cells and use in diagnostic methods
WO2010093993A2 (fr) * 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Utilisation d'antagonistes de la protéine stimulant les lymphocytes b afin de favoriser la tolérance aux greffes
WO2011160086A2 (fr) 2010-06-18 2011-12-22 Human Genome Sciences, Inc. Utilisation d'antagonistes d'une protéine stimulant les lymphocytes b en vue du traitement de l'asthme et d'autres affections allergiques et inflammatoires du système respiratoire

Also Published As

Publication number Publication date
MXPA02012434A (es) 2004-09-06
US20060062789A1 (en) 2006-03-23
EP2275449A1 (fr) 2011-01-19
US8101181B2 (en) 2012-01-24
HK1051697A1 (en) 2003-08-15
US7605236B2 (en) 2009-10-20
CN1279055C (zh) 2006-10-11
CY1118317T1 (el) 2017-06-28
KR20100133025A (ko) 2010-12-20
CA2407910A1 (fr) 2002-01-10
CY2012003I1 (el) 2016-12-14
US20030059937A1 (en) 2003-03-27
AU2009200977B2 (en) 2012-11-15
KR101155294B1 (ko) 2013-03-07
FR12C0001I2 (fr) 2014-05-16
AU2001268427B2 (en) 2007-03-29
EP1294769A4 (fr) 2004-07-28
EP2275449B1 (fr) 2016-09-28
KR20030038557A (ko) 2003-05-16
ES2358885T3 (es) 2011-05-16
CA2407910C (fr) 2013-03-12
LU91926I2 (fr) 2012-03-05
ES2609583T3 (es) 2017-04-21
CY1118363T1 (el) 2017-06-28
FR12C0001I1 (fr) 2012-02-24
KR101287395B1 (ko) 2014-11-04
US20100003259A1 (en) 2010-01-07
JP2009095346A (ja) 2009-05-07
CY1112793T1 (el) 2016-02-10
PT2275449T (pt) 2016-12-27
EP2281843A1 (fr) 2011-02-09
JP4902618B2 (ja) 2012-03-21
NZ522700A (en) 2006-02-24
KR20120053525A (ko) 2012-05-25
ES2609016T3 (es) 2017-04-18
CY2012003I2 (el) 2020-05-29
EP2281842A1 (fr) 2011-02-09
AU6842701A (en) 2002-01-14
US9187548B2 (en) 2015-11-17
US7138501B2 (en) 2006-11-21
CN1492878A (zh) 2004-04-28
PT2281843T (pt) 2017-01-02
AU2009200977A1 (en) 2009-04-02
EP1294769A1 (fr) 2003-03-26
DK1294769T3 (da) 2011-04-26
US20120121606A1 (en) 2012-05-17
DE60143798D1 (de) 2011-02-17
EP1294769B1 (fr) 2011-01-05
ATE494304T1 (de) 2011-01-15
JP4902087B2 (ja) 2012-03-21
WO2002002641A1 (fr) 2002-01-10
KR20060088905A (ko) 2006-08-07
JP2004509615A (ja) 2004-04-02
EP2281843B1 (fr) 2016-10-12

Similar Documents

Publication Publication Date Title
BE2012C005I2 (fr)
WO2003055979A3 (fr) Anticorps se liant à blys selon un mode immunospécifique
DK1385864T3 (da) Anti-VEGF-2-antistoffer
WO2003054216A3 (fr) Anticorps se liant de maniere immunospecifique a des recepteurs trail
MXPA03010747A (es) Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.
LU93274I2 (fr) Elotuzumab
BR9811946A (pt) Método para prevenção ou tratamento de distúrbios e doenças dependentes de estrogênio
BRPI0313792B8 (pt) utilização de proteína de eritropoetina, método para tratamento de distúrbios de distribuição de ferro em diabetes e medicamento para o seu tratamento
PT911331E (pt) Compostos de dibenzoxazepina substituidos composicoes farmaceuticas e metodos de utilizacao
BR0312768A (pt) Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
BR0009524A (pt) Uso de um composto, e, composição farmacêutica ou veterinaria
BR0110208A (pt) Composições e terapias para distúrbios associados com hiperlipidemia
KR100292396B1 (fr)
WO2005016236A3 (fr) Anticorps se liant de maniere immunospecifique aux recepteurs trail
WO2002079377A3 (fr) Anticorps a liaison immunospecifique avec les recepteurs 'trail'
WO2004016753A3 (fr) Anticorps se fixant de facon immunospecifique a des recepteurs trail
WO2003042367A3 (fr) Anticorps se liant specifiquement au niveau immunitaire a des recepteurs trail
BR0213633A (pt) Método e composto para tratar de uma doença associada com recrutamento e/ou ativação aberrante de leucócitos
WO2002036166A8 (fr) Procedes et compositions stimulant le cd45 et supprimant de ce fait l'activation du microglial associee a la maladie d'alzheimer